Also known as: Metastatic Melanoma / Malignant melanoma, metastatic / Metastatic malignant melanoma
DrugDrug NameDrug Description
DB00041AldesleukinAldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon for this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125.
DB00515CisplatinCisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
DB05239CobimetinibCobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or metastatic BRAF V600 mutation-positive melanoma.
DB08912DabrafenibDabrafenib mesylate is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. FDA approved on May 29, 2013.
DB00851DacarbazineAn antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma.
DB00619ImatinibImatinib is a small molecule kinase inhibitor used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec (USA) or Glivec (Europe/Australia) as its mesylate salt, imatinib mesilate (INN). It is occasionally referred to as CGP57148B or STI571 (especially in older publications). It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies. It is the first member of a new class of agents that act by inhibiting particular tyrosine kinase enzymes, instead of non-specifically inhibiting rapidly dividing cells.
DB06186IpilimumabIpilimumab, a recombinant human monoclonal antibody (IgG1 kappa immunoglobin), is an antineoplastic agent developed by Bristol-Myers Squibb and Medarex for the treatment of unresectable or metastatic melanoma in adults. Ipilimumab received FDA approved on March 25, 2011. In October 2015, the FDA approved expanded the indications for Ipilimumab, allowing it to be used to reduce the risk of the deadly skin cancer returning after surgery.
DB09035NivolumabNivolumab is a fully human IgG4 monoclonal antibody that acts as an immunomodulator by blocking ligand activation of programmed cell death 1 (PD-1) receptor on T cells. It is indicated for use in patients with unresectable (cannot be surgically removed) or metastatic melanoma who no longer respond to other drugs. Nivolumab is administered as an intravenous infusion over 60 minutes every 2 weeks.
DB01229PaclitaxelPaclitaxel is a mitotic inhibitor used in cancer chemotherapy. It was discovered in a US National Cancer Institute program at the Research Triangle Institute in 1967 when Monroe E. Wall and Mansukh C. Wani isolated it from the bark of the Pacific yew tree, Taxus brevifolia and named it taxol. Later it was discovered that endophytic fungi in the bark synthesize paclitaxel. When it was developed commercially by Bristol-Myers Squibb (BMS), the generic name was changed to paclitaxel and the BMS compound is sold under the trademark Taxol. In this formulation, paclitaxel is dissolved in Kolliphor EL and ethanol, as a delivery agent. A newer formulation, in which paclitaxel is bound to albumin, is sold under the trademark Abraxane. [Wikipedia]
DB09037PembrolizumabPembrolizumab is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2. It is used for the treatment of several types of cancer such as, Melanoma, Non-Small Cell Lung Cancer and Head and Neck Cancer. Due to its success in clinical trials, pembrolizumab was approved early to allow quick patient access and was given breakthrough therapy and orphan drug designation. Pembrolizumab (as Keytruda) was approved by the U.S. Food and Drug Administration to treat advanced cases of the most common type of lung malignancy, non-small cell lung cancer on Oct. 2, 2015. Keytruda was additionally approved for the treatment of Classical Hodgkin Lymphoma (cHL) in March, 2017.
DB08911TrametinibTrametinib dimethyl sulfoxide is a kinase inhibitor. Each 1-mg tablet contains 1.127 mg trametinib dimethyl sulfoxide equivalent to 1 mg of trametinib non-solvated parent. FDA approved on May 29, 2013.
DB08881VemurafenibVemurafenib is a BRAF enzyme inhibitor developed by Plexxikon and Genentech for the treatment of late-stage melanoma. The cobasĀ® 4800 BRAF B600 mutation test provided by Roche Molecular Systems is the diagnostic test to confirm eligibility for treatment. FDA approved on August 17, 2011 under the company Hoffmann La Roche.
DB00570VinblastineAntitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)
DrugDrug NameTargetType
DB00041AldesleukinInterleukin-2 receptor subunit betatarget
DB00041AldesleukinInterleukin-2 receptor subunit alphatarget
DB00041AldesleukinCytokine receptor common subunit gammatarget
DB00041AldesleukinProstaglandin G/H synthase 2enzyme
DB00041AldesleukinCytosolic phospholipase A2enzyme
DB00041AldesleukinCytochrome P450 3A4enzyme
DB00041AldesleukinXanthine dehydrogenase/oxidaseenzyme
DB00041AldesleukinCytochrome P450 2E1enzyme
DB00515CisplatinDNAtarget
DB00515CisplatinCanalicular multispecific organic anion transporter 2transporter
DB00515CisplatinMultidrug resistance-associated protein 5transporter
DB00515CisplatinCanalicular multispecific organic anion transporter 1transporter
DB00515CisplatinSolute carrier family 22 member 2transporter
DB00515CisplatinHigh affinity copper uptake protein 1transporter
DB00515CisplatinProbable low affinity copper uptake protein 2transporter
DB00515CisplatinMultidrug resistance-associated protein 6transporter
DB00515CisplatinMultidrug resistance protein 1transporter
DB00515CisplatinCopper-transporting ATPase 2transporter
DB00515CisplatinCopper-transporting ATPase 1transporter
DB00515CisplatinProstaglandin G/H synthase 2enzyme
DB00515CisplatinMyeloperoxidaseenzyme
DB00515CisplatinXanthine dehydrogenase/oxidaseenzyme
DB00515CisplatinArylamine N-acetyltransferaseenzyme
DB00515CisplatinCytochrome P450 2C9enzyme
DB00515CisplatinCytochrome P450 2B6enzyme
DB00515CisplatinCholinesteraseenzyme
DB00515CisplatinCytochrome P450 4A11enzyme
DB00515CisplatinATP-binding cassette sub-family G member 2transporter
DB00515CisplatinGlutathione S-transferase theta-1enzyme
DB00515CisplatinMetallothionein-1Aenzyme
DB00515CisplatinMetallothionein-2enzyme
DB00515CisplatinSuperoxide dismutase [Cu-Zn]enzyme
DB00515CisplatinGlutathione S-transferase Penzyme
DB00515CisplatinNAD(P)H dehydrogenase [quinone] 1enzyme
DB00515CisplatinGlutathione S-transferase Mu 1enzyme
DB00515CisplatinDNA-3-methyladenine glycosylasetarget
DB00515CisplatinAlpha-2-macroglobulintarget
DB00515CisplatinSerum albumincarrier
DB00515CisplatinSerotransferrintarget
DB00515CisplatinCopper transport protein ATOX1target
DB05239CobimetinibDual specificity mitogen-activated protein kinase kinase 1target
DB05239CobimetinibCYP3Aenzyme
DB05239CobimetinibMultidrug resistance protein 1enzyme
DB05239CobimetinibSolute carrier organic anion transporter family member 1B1transporter
DB05239CobimetinibSolute carrier organic anion transporter family member 1B3transporter
DB05239CobimetinibATP-binding cassette sub-family G member 2transporter
DB08912DabrafenibCytochrome P450 3A4enzyme
DB08912DabrafenibCytochrome P450 2C8enzyme
DB08912DabrafenibMultidrug resistance protein 1transporter
DB08912DabrafenibATP-binding cassette sub-family G member 2transporter
DB08912DabrafenibSolute carrier organic anion transporter family member 1B1transporter
DB08912DabrafenibSolute carrier organic anion transporter family member 1B3transporter
DB08912DabrafenibSolute carrier family 22 member 6transporter
DB08912DabrafenibSolute carrier family 22 member 8transporter
DB08912DabrafenibSerine/threonine-protein kinase B-raftarget
DB08912DabrafenibRAF proto-oncogene serine/threonine-protein kinasetarget
DB08912DabrafenibSerine/threonine-protein kinase SIK1target
DB08912DabrafenibSerine/threonine-protein kinase Nek11target
DB08912DabrafenibLIM domain kinase 1target
DB00851DacarbazineDNA polymerase alpha subunit Btarget
DB00851DacarbazineCytochrome P450 1A1enzyme
DB00851DacarbazineCytochrome P450 1A2enzyme
DB00851DacarbazineCytochrome P450 2E1enzyme
DB00851Dacarbazine6-phosphogluconate dehydrogenase, decarboxylatingtarget
DB00851DacarbazineDNAtarget
DB00619ImatinibPlatelet-derived growth factor receptor betatarget
DB00619ImatinibTyrosine-protein kinase ABL1target
DB00619ImatinibMast/stem cell growth factor receptor Kittarget
DB00619ImatinibRET proto-oncogenetarget
DB00619ImatinibHigh affinity nerve growth factor receptortarget
DB00619ImatinibMacrophage colony-stimulating factor 1 receptortarget
DB00619ImatinibPlatelet-derived growth factor receptor alphatarget
DB00619ImatinibEpithelial discoidin domain-containing receptor 1target
DB00619ImatinibCytochrome P450 3A4enzyme
DB00619ImatinibBCR/ABL fusion protein isoform X9target
DB00619ImatinibCytochrome P450 1A2enzyme
DB00619ImatinibCytochrome P450 2D6enzyme
DB00619ImatinibCytochrome P450 2C9enzyme
DB00619ImatinibCytochrome P450 2C19enzyme
DB00619ImatinibCytochrome P450 3A5enzyme
DB00619ImatinibCytochrome P450 3A7enzyme
DB00619ImatinibSolute carrier family 22 member 1transporter
DB00619ImatinibMultidrug resistance protein 1transporter
DB00619ImatinibSolute carrier family 22 member 2transporter
DB00619ImatinibATP-binding cassette sub-family G member 2transporter
DB00619ImatinibATP-binding cassette sub-family A member 3transporter
DB00619ImatinibProstaglandin G/H synthase 1enzyme
DB00619ImatinibSerum albumincarrier
DB00619ImatinibAlpha-1-acid glycoprotein 1carrier
DB06186IpilimumabCytotoxic T-lymphocyte protein 4target
DB09035NivolumabProgrammed cell death protein 1target
DB01229PaclitaxelApoptosis regulator Bcl-2target
DB01229PaclitaxelTubulin beta-1 chaintarget
DB01229PaclitaxelCytochrome P450 2C8enzyme
DB01229PaclitaxelCytochrome P450 3A4enzyme
DB01229PaclitaxelCytochrome P450 3A5enzyme
DB01229PaclitaxelCytochrome P450 3A7enzyme
DB01229PaclitaxelCytochrome P450 2C9enzyme
DB01229PaclitaxelBile salt export pumptransporter
DB01229PaclitaxelMultidrug resistance protein 1transporter
DB01229PaclitaxelMultidrug resistance-associated protein 1transporter
DB01229PaclitaxelMultidrug resistance-associated protein 7transporter
DB01229PaclitaxelCytochrome P450 19A1enzyme
DB01229PaclitaxelCytochrome P450 1B1enzyme
DB01229PaclitaxelSolute carrier organic anion transporter family member 1B3transporter
DB01229PaclitaxelNuclear receptor subfamily 1 group I member 2target
DB01229PaclitaxelMicrotubule-associated protein 4target
DB01229PaclitaxelMicrotubule-associated protein 2target
DB01229PaclitaxelMicrotubule-associated protein tautarget
DB01229PaclitaxelATP-binding cassette sub-family G member 2transporter
DB01229PaclitaxelCanalicular multispecific organic anion transporter 1transporter
DB09037PembrolizumabProgrammed cell death protein 1target
DB08911TrametinibCytochrome P450 2C8enzyme
DB08911TrametinibCytochrome P450 3A4enzyme
DB08911TrametinibDual specificity mitogen-activated protein kinase kinase 1target
DB08911TrametinibDual specificity mitogen-activated protein kinase kinase 2target
DB08881VemurafenibSerum albumincarrier
DB08881VemurafenibAlpha-1-acid glycoprotein 1carrier
DB08881VemurafenibCytochrome P450 1A2enzyme
DB08881VemurafenibCytochrome P450 2D6enzyme
DB08881VemurafenibCytochrome P450 3A4enzyme
DB08881VemurafenibSerine/threonine-protein kinase B-raftarget
DB08881VemurafenibMultidrug resistance-associated protein 1transporter
DB08881VemurafenibATP-binding cassette sub-family G member 2transporter
DB00570VinblastineTubulin beta chaintarget
DB00570VinblastineTranscription factor AP-1target
DB00570VinblastineCytochrome P450 3A4enzyme
DB00570VinblastineMultidrug resistance protein 1transporter
DB00570VinblastineMultidrug resistance-associated protein 1transporter
DB00570VinblastineCanalicular multispecific organic anion transporter 1transporter
DB00570VinblastineMultidrug resistance-associated protein 6transporter
DB00570VinblastineBile salt export pumptransporter
DB00570VinblastineSolute carrier family 22 member 2transporter
DB00570VinblastineTubulin alpha-1A chaintarget
DB00570VinblastineTubulin delta chaintarget
DB00570VinblastineTubulin epsilon chaintarget
DB00570VinblastineTubulin gamma-1 chaintarget
DB00570VinblastineCytochrome P450 2D6enzyme
DrugDrug NamePhaseStatusCount
DB00724Imiquimod0Not Yet Recruiting1
DB09037Pembrolizumab0Not Yet Recruiting1
DB12001Abemaciclib1Recruiting1
DB08885Aflibercept1Recruiting1
DB00041Aldesleukin1Completed1
DB00041Aldesleukin1Withdrawn1
DB12768BCG vaccine1Terminated1
DB00515Cisplatin1Completed1
DB00531Cyclophosphamide1Recruiting1
DB00531Cyclophosphamide1Terminated1
DB00531Cyclophosphamide1Withdrawn1
DB08912Dabrafenib1Recruiting2
DB08912Dabrafenib1Withdrawn1
DB01248Docetaxel1Completed1
DB01099Flucytosine1Recruiting1
DB01073Fludarabine1Recruiting1
DB01073Fludarabine1Terminated1
DB01073Fludarabine1Withdrawn1
DB00441Gemcitabine1Recruiting1
DB11918Guadecitabine1Recruiting1
DB06186Ipilimumab1Active Not Recruiting1
DB06186Ipilimumab1Recruiting3
DB06186Ipilimumab1Terminated1
DB09078Lenvatinib1Completed1
DB00683Midazolam1Recruiting1
DB09035Nivolumab1Active Not Recruiting1
DB09035Nivolumab1Recruiting1
DB09035Nivolumab1Withdrawn1
DB09037Pembrolizumab1Recruiting2
DB11759Pevonedistat1Completed1
DB00073Rituximab1Terminated1
DB01268Sunitinib1Active Not Recruiting1
DB00853Temozolomide1Active Not Recruiting1
DB00853Temozolomide1Completed2
DB08911Trametinib1Recruiting2
DB08911Trametinib1Withdrawn1
DB11771Tremelimumab1Active Not Recruiting1
DB07232Veliparib1Completed1
DB00041Aldesleukin1 / 2Completed2
DB00041Aldesleukin1 / 2Recruiting1
DB00041Aldesleukin1 / 2Terminated1
DB01169Arsenic trioxide1 / 2Terminated1
DB00112Bevacizumab1 / 2Completed1
DB00112Bevacizumab1 / 2Withdrawn1
DB00515Cisplatin1 / 2Completed2
DB00531Cyclophosphamide1 / 2Completed1
DB00531Cyclophosphamide1 / 2Recruiting2
DB00531Cyclophosphamide1 / 2Terminated3
DB08912Dabrafenib1 / 2Recruiting2
DB00851Dacarbazine1 / 2Completed1
DB01254Dasatinib1 / 2Completed1
DB01262Decitabine1 / 2Completed1
DB01262Decitabine1 / 2Recruiting1
DB00822Disulfiram1 / 2Terminated1
DB01073Fludarabine1 / 2Completed1
DB01073Fludarabine1 / 2Recruiting2
DB01073Fludarabine1 / 2Terminated3
DB05217GMX17771 / 2Terminated1
DB11795GSK-26367711 / 2Recruiting1
DB12827Indoximod1 / 2Recruiting1
DB06186Ipilimumab1 / 2Active Not Recruiting1
DB06186Ipilimumab1 / 2Completed1
DB06186Ipilimumab1 / 2Recruiting4
DB06186Ipilimumab1 / 2Terminated1
DB06186Ipilimumab1 / 2Withdrawn1
DB12340Navitoclax1 / 2Recruiting1
DB09035Nivolumab1 / 2Not Yet Recruiting1
DB09035Nivolumab1 / 2Recruiting3
DB12191Obatoclax1 / 2Terminated1
DB06603Panobinostat1 / 2Completed1
DB00022Peginterferon alfa-2b1 / 2Recruiting1
DB09037Pembrolizumab1 / 2Recruiting4
DB00020Sargramostim1 / 2Recruiting1
DB00853Temozolomide1 / 2Active Not Recruiting1
DB00853Temozolomide1 / 2Completed3
DB00853Temozolomide1 / 2Terminated1
DB00853Temozolomide1 / 2Withdrawn1
DB08911Trametinib1 / 2Recruiting2
DB08881Vemurafenib1 / 2Recruiting2
DB00570Vinblastine1 / 2Completed1
DB08885Aflibercept2Active Not Recruiting1
DB00041Aldesleukin2Active Not Recruiting4
DB00041Aldesleukin2Completed5
DB00041Aldesleukin2Recruiting3
DB00041Aldesleukin2Terminated6
DB00928Azacitidine2Recruiting1
DB00112Bevacizumab2Active Not Recruiting1
DB00112Bevacizumab2Completed3
DB00112Bevacizumab2Terminated1
DB00958Carboplatin2Completed2
DB05239Cobimetinib2Recruiting1
DB05239Cobimetinib2Terminated1
DB00531Cyclophosphamide2Active Not Recruiting2
DB00531Cyclophosphamide2Completed3
DB00531Cyclophosphamide2Not Yet Recruiting1
DB00531Cyclophosphamide2Recruiting1
DB00531Cyclophosphamide2Terminated7
DB00531Cyclophosphamide2Withdrawn1
DB08912Dabrafenib2Not Yet Recruiting1
DB08912Dabrafenib2Recruiting2
DB00851Dacarbazine2Active Not Recruiting1
DB00851Dacarbazine2Completed1
DB00851Dacarbazine2Terminated2
DB01254Dasatinib2Recruiting1
DB01248Docetaxel2Completed1
DB12797Ecromeximab2Active Not Recruiting1
DB11718Encorafenib2Recruiting1
DB01590Everolimus2Completed2
DB01590Everolimus2Terminated1
DB01073Fludarabine2Active Not Recruiting2
DB01073Fludarabine2Completed3
DB01073Fludarabine2Not Yet Recruiting1
DB01073Fludarabine2Recruiting1
DB01073Fludarabine2Terminated6
DB09053Ibrutinib2Recruiting1
DB09053Ibrutinib2Suspended1
DB00619Imatinib2Completed1
DB00619Imatinib2Terminated1
DB00034Interferon Alfa-2a, Recombinant2Completed1
DB00105Interferon Alfa-2b, Recombinant2Active Not Recruiting1
DB06186Ipilimumab2Active Not Recruiting4
DB06186Ipilimumab2Completed2
DB06186Ipilimumab2Not Yet Recruiting1
DB06186Ipilimumab2Recruiting3
DB06186Ipilimumab2Terminated2
DB09035Nivolumab2Active Not Recruiting1
DB09035Nivolumab2Not Yet Recruiting1
DB09035Nivolumab2Recruiting3
DB01229Paclitaxel2Active Not Recruiting1
DB01229Paclitaxel2Completed2
DB01229Paclitaxel2Unknown Status1
DB01229Paclitaxel2Withdrawn1
DB09037Pembrolizumab2Not Yet Recruiting1
DB09037Pembrolizumab2Recruiting6
DB09037Pembrolizumab2Suspended1
DB00073Rituximab2Unknown Status1
DB00020Sargramostim2Active Not Recruiting1
DB00020Sargramostim2Completed2
DB01268Sunitinib2Completed1
DB11941Tasisulam2Completed1
DB00853Temozolomide2Completed2
DB08911Trametinib2Not Yet Recruiting1
DB08911Trametinib2Recruiting2
DB07232Veliparib2Completed1
DB08881Vemurafenib2Active Not Recruiting1
DB08881Vemurafenib2Recruiting1
DB08881Vemurafenib2Terminated1
DB00570Vinblastine2Terminated1
DB00361Vinorelbine2Completed1
DB09145Water2Active Not Recruiting1
DB00041Aldesleukin3Recruiting1
DB00531Cyclophosphamide3Recruiting1
DB08912Dabrafenib3Recruiting1
DB00851Dacarbazine3Completed1
DB00851Dacarbazine3Recruiting1
DB01073Fludarabine3Recruiting1
DB06186Ipilimumab3Recruiting2
DB09035Nivolumab3Recruiting1
DB00853Temozolomide3Completed1
DB08911Trametinib3Recruiting1
DB00041Aldesleukin4Terminated1
DB00515Cisplatin4Unknown Status1
DB00851Dacarbazine4Unknown Status1
DB06186Ipilimumab4Terminated1
DB09035Nivolumab4Recruiting1
DB00309Vindesine4Unknown Status1
DB00041AldesleukinNot AvailableActive Not Recruiting2
DB00531CyclophosphamideNot AvailableActive Not Recruiting2
DB00927FamotidineNot AvailableActive Not Recruiting1
DB01073FludarabineNot AvailableActive Not Recruiting1
DB06186IpilimumabNot AvailableActive Not Recruiting1
DB01042MelphalanNot AvailableRecruiting1
DB09037PembrolizumabNot AvailableRecruiting1
DB12978PexidartinibNot AvailableRecruiting1